Coeptis Therapeutics Inc. (OTCPK:COEP) agreed to acquire TLR5 Immunity Receptor Agnonist Platform from Statera Biopharma, Inc. (NasdaqCM:STAB) for $6 million on April 6, 2022. The consummation of the transaction is contingent upon negotiation of a definitive agreement and satisfaction of a number of closing conditions, including a financing contingency.

Coeptis Therapeutics Inc. (OTCPK:COEP) cancelled the acquisition of TLR5 Immunity Receptor Agnonist Platform from Statera Biopharma, Inc. (NasdaqCM:STAB) on August 22, 2022. The termination was based on the mutual determination by both parties, and no termination penalties were incurred by Coeptis or Statera.